Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cx401 (Autologous ASCs) for Complex Perianal Fistulas
NCT00475410Phase 3Completed
- Sponsor
- TiGenix
- Start
- Feb 2007
- Primary completion
- Aug 2009
- Modality
- Stem Cell Therapies
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of autologous adipose-derived mesenchymal stromal cells in anal fistula (3 arms), sponsored by TiGenix. Primary endpoint: Closure of fistulas at 26 weeks. Started Feb 2007; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
anal fistula
Beyond the preview
Go deeper on NCT00475410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475410.